Dimitry Nuyten, Arcus CMO
December 19, 2022 05:01 PM ESTUpdated 05:25 PM
Bioregnum
R&D

Gilead and Ar­cus want you to be­lieve again in TIG­IT. But mixed ARC-7 da­ta are rolling out to a tough crowd

Roche let the air out of the TIG­IT par­ty bal­loon with a pair of crush­ing Phase III fail­ures. Now Gilead $GILD and Ar­cus $RCUS are …

Endpoints Premium

This article is available only to Premium subscribers

Upgrade to Premium for unlimited access and Premium exclusives.

UPGRADE
TRENDING NOW

Trump asks 'very tough hom­bre' Dr. Oz to lead MFN talks

US warns drug­mak­ers against mis­rep­re­sent­ing cost of im­port­ed prod­ucts

About 5% of CBER and CDER left af­ter FDA staff cuts, analy­sis finds

Meet the ‘first sale’ rule: A cus­toms loop­hole phar­ma com­pa­nies could use to ease tar­iff im­pact

End­points 100 biotech sur­vey: Wel­come to the sum­mer of biotech’s dis­con­tent

sponsored

Does your sup­ply chain hold up un­der pres­sure for high-risk tem­per­a­ture-crit­i­cal ship­ments?

A service from the Financial Times